First UK patient enrolled onto Novartis retinal vascular disease study

Article

Luminous, a program created to develop the understanding of retinal vascular diseases, has enrolled its first patient this month.

Luminous, a program created to develop the understanding of retinal vascular diseases, has enrolled its first patient this month.

Novartis Pharmaceuticals has launched Luminous for wet age-related macular degeneration (AMD), diabetic macular oedema (DME) and visual impairment due to macular oedema secondary to retinal vein occlusion (RVO).

The program, in conjunction with leading ophthalmologists and the AMD Alliance International, will gather prospective data from 30,000 patients worldwide and will also include information from existing ranibizumab registries.

Christopher Brand, Royal Hallamshire Hospital, Sheffield, is the leading consultant ophthalmologist involved in the enrolment of the first UK patient. He said: "This programme will enable us to facilitate real-time comparisons between the results seen in the UK with different ranibizumab treatment regimens in clinics around the world. The information we receive could help us provide better care for our patients and identify the best course of therapy for each individual.”

Dr Timothy Cave, Chief Scientific Officer, Novartis Pharmaceutcals, explained: "A wealth of data is already available on the safety and efficacy of ranibizumab from clinical trials, but we hope Luminous will further support this data and provide information on the long-term outcomes in clinical practice. Novartis is committed to ophthalmology and improving understanding and treatment of vascular diseases.”

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.